补充Omega-3脂肪酸治疗持续性冠状病毒相关嗅觉功能障碍

IF 2.5 3区 医学 Q1 OTORHINOLARYNGOLOGY American Journal of Rhinology & Allergy Pub Date : 2023-09-01 DOI:10.1177/19458924231174799
David K Lerner, Katherine L Garvey, Annie Arrighi-Allisan, Evan Kominsky, Andrey Filimonov, Abdurrahman Al-Awady, Peter Filip, Katherine Liu, Sen Ninan, Todd Spock, Benjamin Tweel, Maaike van Gerwen, Madeleine Schaberg, Patrick Colley, Anthony Del Signore, Satish Govindaraj, Alfred Marc Iloreta
{"title":"补充Omega-3脂肪酸治疗持续性冠状病毒相关嗅觉功能障碍","authors":"David K Lerner,&nbsp;Katherine L Garvey,&nbsp;Annie Arrighi-Allisan,&nbsp;Evan Kominsky,&nbsp;Andrey Filimonov,&nbsp;Abdurrahman Al-Awady,&nbsp;Peter Filip,&nbsp;Katherine Liu,&nbsp;Sen Ninan,&nbsp;Todd Spock,&nbsp;Benjamin Tweel,&nbsp;Maaike van Gerwen,&nbsp;Madeleine Schaberg,&nbsp;Patrick Colley,&nbsp;Anthony Del Signore,&nbsp;Satish Govindaraj,&nbsp;Alfred Marc Iloreta","doi":"10.1177/19458924231174799","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of omega-3 fatty acid (O3FA) supplementation in the treatment of COVID-related olfactory dysfunction (OD).</p><p><strong>Methods: </strong>Patients with laboratory-confirmed or clinically-suspected COVID-19 infection and new-onset OD from August 2020 to November 2021 were prospectively recruited. Patients with quantitative OD, defined as a brief smell identification test (BSIT) score of 9 or less, were eligible for study inclusion. The experimental group received 2 g of O3FA supplementation, while the control group received an identical placebo to be taken daily for 6 weeks. The primary outcome was a change in BSIT score between the initial and 6-week follow-up tests.</p><p><strong>Results: </strong>One hundred and seventeen patients were included in the analysis, including 57 patients in the O3FA group and 60 in the placebo group. O3FA group patients demonstrated a mean BSIT improvement of 1.12 ± 1.99 compared to 0.68 ± 1.86 in the placebo group (<i>p</i> = 0.221). Seventy-seven patients, 42 within the O3FA group and 35 in the placebo group, completed a follow-up BSIT survey at an average of 717.8 days from study onset. At long-term follow-up, there was an average BSIT score improvement of 1.72 within the O3FA group compared to 1.76 within the placebo group (<i>p</i> = 0.948).</p><p><strong>Conclusion: </strong>Among patients with persistent COVID-related OD, our study showed no clear evidence of relative short-term or long-term olfactory recovery among patients receiving high doses of O3FA supplementation.</p>","PeriodicalId":7650,"journal":{"name":"American Journal of Rhinology & Allergy","volume":"37 5","pages":"531-540"},"PeriodicalIF":2.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Omega-3 Fatty Acid Supplementation for the Treatment of Persistent COVID-Related Olfactory Dysfunction.\",\"authors\":\"David K Lerner,&nbsp;Katherine L Garvey,&nbsp;Annie Arrighi-Allisan,&nbsp;Evan Kominsky,&nbsp;Andrey Filimonov,&nbsp;Abdurrahman Al-Awady,&nbsp;Peter Filip,&nbsp;Katherine Liu,&nbsp;Sen Ninan,&nbsp;Todd Spock,&nbsp;Benjamin Tweel,&nbsp;Maaike van Gerwen,&nbsp;Madeleine Schaberg,&nbsp;Patrick Colley,&nbsp;Anthony Del Signore,&nbsp;Satish Govindaraj,&nbsp;Alfred Marc Iloreta\",\"doi\":\"10.1177/19458924231174799\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the efficacy of omega-3 fatty acid (O3FA) supplementation in the treatment of COVID-related olfactory dysfunction (OD).</p><p><strong>Methods: </strong>Patients with laboratory-confirmed or clinically-suspected COVID-19 infection and new-onset OD from August 2020 to November 2021 were prospectively recruited. Patients with quantitative OD, defined as a brief smell identification test (BSIT) score of 9 or less, were eligible for study inclusion. The experimental group received 2 g of O3FA supplementation, while the control group received an identical placebo to be taken daily for 6 weeks. The primary outcome was a change in BSIT score between the initial and 6-week follow-up tests.</p><p><strong>Results: </strong>One hundred and seventeen patients were included in the analysis, including 57 patients in the O3FA group and 60 in the placebo group. O3FA group patients demonstrated a mean BSIT improvement of 1.12 ± 1.99 compared to 0.68 ± 1.86 in the placebo group (<i>p</i> = 0.221). Seventy-seven patients, 42 within the O3FA group and 35 in the placebo group, completed a follow-up BSIT survey at an average of 717.8 days from study onset. At long-term follow-up, there was an average BSIT score improvement of 1.72 within the O3FA group compared to 1.76 within the placebo group (<i>p</i> = 0.948).</p><p><strong>Conclusion: </strong>Among patients with persistent COVID-related OD, our study showed no clear evidence of relative short-term or long-term olfactory recovery among patients receiving high doses of O3FA supplementation.</p>\",\"PeriodicalId\":7650,\"journal\":{\"name\":\"American Journal of Rhinology & Allergy\",\"volume\":\"37 5\",\"pages\":\"531-540\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Rhinology & Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/19458924231174799\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Rhinology & Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/19458924231174799","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:评价补充omega-3脂肪酸(O3FA)治疗新冠肺炎相关嗅觉功能障碍(OD)的疗效。方法:前瞻性招募2020年8月至2021年11月实验室确诊或临床疑似COVID-19感染并新发OD的患者。定量OD的患者,定义为短暂气味识别测试(BSIT)得分为9或更低,符合研究纳入条件。实验组接受2g O3FA补充,而对照组接受相同的安慰剂,每天服用6周。主要结果是初始和6周随访测试之间BSIT评分的变化。结果:117例患者纳入分析,其中O3FA组57例,安慰剂组60例。O3FA组患者的平均BSIT改善为1.12±1.99,而安慰剂组为0.68±1.86 (p = 0.221)。77名患者,42名在O3FA组,35名在安慰剂组,在研究开始后平均717.8天完成了BSIT随访调查。在长期随访中,O3FA组的平均BSIT评分改善为1.72,而安慰剂组为1.76 (p = 0.948)。结论:在持续的covid相关OD患者中,我们的研究显示,接受高剂量O3FA补充的患者没有明显的短期或长期嗅觉恢复的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Omega-3 Fatty Acid Supplementation for the Treatment of Persistent COVID-Related Olfactory Dysfunction.

Objective: To evaluate the efficacy of omega-3 fatty acid (O3FA) supplementation in the treatment of COVID-related olfactory dysfunction (OD).

Methods: Patients with laboratory-confirmed or clinically-suspected COVID-19 infection and new-onset OD from August 2020 to November 2021 were prospectively recruited. Patients with quantitative OD, defined as a brief smell identification test (BSIT) score of 9 or less, were eligible for study inclusion. The experimental group received 2 g of O3FA supplementation, while the control group received an identical placebo to be taken daily for 6 weeks. The primary outcome was a change in BSIT score between the initial and 6-week follow-up tests.

Results: One hundred and seventeen patients were included in the analysis, including 57 patients in the O3FA group and 60 in the placebo group. O3FA group patients demonstrated a mean BSIT improvement of 1.12 ± 1.99 compared to 0.68 ± 1.86 in the placebo group (p = 0.221). Seventy-seven patients, 42 within the O3FA group and 35 in the placebo group, completed a follow-up BSIT survey at an average of 717.8 days from study onset. At long-term follow-up, there was an average BSIT score improvement of 1.72 within the O3FA group compared to 1.76 within the placebo group (p = 0.948).

Conclusion: Among patients with persistent COVID-related OD, our study showed no clear evidence of relative short-term or long-term olfactory recovery among patients receiving high doses of O3FA supplementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.60
自引率
11.50%
发文量
82
审稿时长
4-8 weeks
期刊介绍: The American Journal of Rhinology & Allergy is a peer-reviewed, scientific publication committed to expanding knowledge and publishing the best clinical and basic research within the fields of Rhinology & Allergy. Its focus is to publish information which contributes to improved quality of care for patients with nasal and sinus disorders. Its primary readership consists of otolaryngologists, allergists, and plastic surgeons. Published material includes peer-reviewed original research, clinical trials, and review articles.
期刊最新文献
Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization. The Effect of the Nasal Structure on the Olfactory Cleft Airflow: A Systematic Review. Common Cold Coronavirus 229E Induces Higher Interferon Stimulating Gene Responses in Human Nasal Epithelial Cells from Patients with Chronic Rhinosinusitis with Polyposis. Doing the Rhinologic Work, From Humans to Mice to Robots. Endoplasmic Reticulum Stress Promotes Telomerase Reverse Transcriptase Expression Contributes to Development of Allergic Rhinitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1